Research programme: CDC25 phosphatase inhibitors - Ipsen

Drug Profile

Research programme: CDC25 phosphatase inhibitors - Ipsen

Alternative Names: Debio 0931; IRC-08364; IRC-083864

Latest Information Update: 02 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ipsen
  • Developer Debiopharm Group
  • Class
  • Mechanism of Action CDC25 phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 02 Sep 2010 Discontinued - Preclinical for Cancer in Switzerland (PO)
  • 07 Sep 2009 CDC25 phosphatase inhibitor, Debio 0931, licensed to Debiopharm Group worldwide
  • 07 Sep 2009 Preclinical trials in Cancer in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top